The provisional entities of RCC in the 2016 WHO classification include Oncocytic RCC occurring after neuroblastoma (increased risk of RCC after prior blastoma appearance similar to MiT family TRCC), thyroid-like follicular RCC (morphologically similar to the follicular carcinoma of the thyroid), Anaplastic Lymphoma Kinase (ALK) rearrangements- associated RCC (resembles medullary carcinomas and associated with sickle cell trait) and RCC with angioleiomyomatous stroma (sporadic or associated with tuberous sclerosis) (9). This evidence concerns the gene ALK and blastoma.